What Reviewers Have Said A published review on retatrutide pointed out that comparator studies with semaglutide and tirzepatide were still lacking and argued that this gap was a major omission in development
Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, et al
Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review
EHP OxyGlow EHP Labs We created OxyGlow to help you RADIATE the best version of you, from the inside out!
Why this launch is important: Weekly therapy starting from 325 setting a new affordability benchmark Available in multi-dose vials & pre-filled pens for flexible treatment Approved by CDSCO based on Phase III clinical study in India Designed to improve access, adherence & long-term outcomes Supported by patient program Sankalp for better therapy initiation This launch comes at a time when India is entering a new era of semaglutide accessibility, driven by patent expiry and increasing competition among pharma leaders
Keloids Explore our comprehensive guide on Keloids, offering insights into causes, symptoms, diagnosis, and various treatment options
